{"id":"fluticasone-mdi","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Dysphonia/hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in lung tissue. It suppresses the production of inflammatory cytokines, chemokines, and adhesion molecules, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The metered-dose inhaler (MDI) formulation delivers the drug directly to the respiratory tract for local anti-inflammatory effects.","oneSentence":"Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:44.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT07324707","phase":"PHASE2","title":"Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma","status":"RECRUITING","sponsor":"Anhui Palo Alto Pharmaceuticals, Inc.","startDate":"2025-10-15","conditions":"Bronchial Asthma","enrollment":30},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT07315555","phase":"NA","title":"Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Community Acquired Pneumonia","enrollment":90},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT01092143","phase":"PHASE2","title":"BI 671800 ED in Steroid-naive Asthmatic Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-18","conditions":"Asthma","enrollment":389},{"nctId":"NCT01103349","phase":"PHASE2","title":"BI 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04-20","conditions":"Asthma","enrollment":243},{"nctId":"NCT01090024","phase":"PHASE2","title":"Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03-01","conditions":"Asthma","enrollment":108},{"nctId":"NCT00540839","phase":"PHASE3","title":"A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Asthma, Bronchial","enrollment":""},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":"COPD","enrollment":""},{"nctId":"NCT00071552","phase":"PHASE4","title":"Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01-31","conditions":"Asthma","enrollment":49},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT05054322","phase":"PHASE2, PHASE3","title":"FLuticasone in cOvid Treatment (FLOT)","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2021-09-22","conditions":"Covid19","enrollment":500},{"nctId":"NCT03879837","phase":"PHASE3","title":"Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-03-25","conditions":"Asthma","enrollment":1902},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT00692978","phase":"PHASE4","title":"Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2008-08","conditions":"Healthy, Asthma","enrollment":30},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03184987","phase":"PHASE3","title":"A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-22","conditions":"Asthma","enrollment":111},{"nctId":"NCT01881412","phase":"NA","title":"Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2012-08","conditions":"Asthma","enrollment":118},{"nctId":"NCT02019758","phase":"PHASE4","title":"Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-01-01","conditions":"Eosinophilic Esophagitis","enrollment":129},{"nctId":"NCT01662778","phase":"PHASE4","title":"The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-12","conditions":"Asthma","enrollment":21},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT02338362","phase":"PHASE4","title":"Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-09","conditions":"Ocular Hypertension, Glaucoma, Open-Angle","enrollment":22},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT01687296","phase":"PHASE3","title":"Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-12","conditions":"Asthma","enrollment":261},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT00695604","phase":"PHASE2","title":"Repeated High-dose Inhaled Corticosteroids for Asthma","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2008-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00214019","phase":"NA","title":"The Effect of Salmeterol on Eosinophil (EOS) Function","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT00370097","phase":"PHASE1","title":"FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Asthma","enrollment":16},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT01321827","phase":"PHASE2, PHASE3","title":"Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-04","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT02141633","phase":"NA","title":"Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment","status":"COMPLETED","sponsor":"University of Miami","startDate":"2013-04","conditions":"Smoking","enrollment":31},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT00369993","phase":"PHASE2","title":"Spacer Comparison In Adult Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Asthma","enrollment":20},{"nctId":"NCT01184118","phase":"NA","title":"DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-03","conditions":"Lung Disease","enrollment":36},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT01216735","phase":"NA","title":"Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-09","conditions":"Tobacco Abuse Smoke","enrollment":32},{"nctId":"NCT02135718","phase":"","title":"ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06","conditions":"Asthma","enrollment":288},{"nctId":"NCT02415179","phase":"NA","title":"Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-05","conditions":"Asthma","enrollment":52},{"nctId":"NCT02403713","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-08","conditions":"Asthma","enrollment":125},{"nctId":"NCT00869596","phase":"PHASE1","title":"Study of Biomarkers of Airway Inflammation (0000-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Airway Inflammation","enrollment":22},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT01332422","phase":"","title":"Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Asthma","enrollment":300},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT00239421","phase":"PHASE4","title":"A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":605},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT01141439","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT01729351","phase":"","title":"Qvar Therapy in Smoking Asthmatics","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2011-11","conditions":"Asthma, Smoking","enrollment":7195},{"nctId":"NCT00404261","phase":"PHASE4","title":"Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Asthma","enrollment":132},{"nctId":"NCT00307970","phase":"PHASE4","title":"Impact of Anti-static Chamber/Mask","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-04","conditions":"Asthma","enrollment":12},{"nctId":"NCT00308932","phase":"PHASE4","title":"Effect of Age and Device on Delivery of Fluticasone","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT00393991","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-07","conditions":"Asthma","enrollment":475},{"nctId":"NCT00394199","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":357},{"nctId":"NCT00830102","phase":"PHASE2","title":"Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2004-10","conditions":"Asthma","enrollment":64},{"nctId":"NCT00393952","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":557},{"nctId":"NCT01141452","phase":"","title":"Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":815377},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT00394121","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-03","conditions":"Asthma","enrollment":400},{"nctId":"NCT01141465","phase":"","title":"Real-world Effectiveness of Combination Therapy in Asthma","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2001-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT00448435","phase":"PHASE3","title":"Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Bronchial Asthma","enrollment":51},{"nctId":"NCT00867737","phase":"PHASE4","title":"Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)","status":"UNKNOWN","sponsor":"Allergy and Asthma Center of El Paso","startDate":"2008-09","conditions":"Asthma","enrollment":30},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"HYPOCHLORAEMIA"},{"count":1,"reaction":"HYPONATRAEMIA"},{"count":1,"reaction":"SUICIDAL IDEATION"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flovent"],"phase":"marketed","status":"active","brandName":"Fluticasone MDI","genericName":"Fluticasone MDI","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}